Ranbaxy Laboratories, one of the leading pharma players, announced the launch of ABSORICA 25 mg and 35 mg capsules into the US healthcare market. ABSORICA has become the most prescribed branded oral isotretinoin in the US as per a recent independent survey conducted with dermatologists.
The product is licenced by Ranbaxy from Cipher Pharmaceuticals. It is indicated for the treatment of severe recalcitrant nodular acne in patients 12 years of age and older.
Ashish Anvekar, vice president of brand division North America, Ranbaxy said, ''Since isotretinoin dosing is weight-based, we are most pleased to make available these valuable, additional dosing options exclusively for ABSORICA. This will give prescribers the enhanced flexibility, to tailor the isotretinoin therapy depending on the patient's weight and benefit the group of patients who are in that weight range, irrespective of their dietary intake. Ranbaxy continuously seeks to innovate and bring value based options to the specially of dermatology and patirnets.''
Shares of the company declined Rs 1.4, or 0.22%, to settle at Rs 638.30. The total volume of shares traded was 90,255 at the BSE (Wednesday).